Repros Therapeutics: PRAC Conclusion On TRT Helps Case For Androxal, Says Brean Capital
In a research report published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target.
Aschoff commented: “Last Friday, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that testosterone replacement therapy (TRT) were not shown to increase CV risk in men with hypogonadism, based on an EU-wide review of TRT. The PRAC recommendation is subject to the final decision from relevant EMA departments. We continue to emphasize that Androxal is differentiated from TRT, and we optimistically look forward to the one-year safety data with Androxal in mid-October, Analyst Day on October 31, and Repros’ type B pre-NDA meeting with the FDA in the first half of November to better understand the FDA’s stance on the NDA for Androxal.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 11.7% and a 49.4% success rate. Aschoff has a -28.5% average return when recommending RPRX, and is ranked #221 out of 3340 analysts.